{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:12:52Z","timestamp":1782951172678,"version":"3.54.5"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR080659"],"award-info":[{"award-number":["R01 AR080659"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR077607"],"award-info":[{"award-number":["R01 AR077607"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR070253"],"award-info":[{"award-number":["P30 AR070253"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR072577"],"award-info":[{"award-number":["P30 AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01 HL155522"],"award-info":[{"award-number":["R01 HL155522"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R. Bruce and Joan M. Mickey Research Scholar Fund"},{"DOI":"10.13039\/100020167","name":"Gordon and Llura Gund Foundation","doi-asserted-by":"publisher","award":["Llura Gund Award"],"award-info":[{"award-number":["Llura Gund Award"]}],"id":[{"id":"10.13039\/100020167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40266-024-01175-0","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T02:15:08Z","timestamp":1736734508000},"page":"81-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People"],"prefix":"10.1007","volume":"42","author":[{"given":"Kevin T.","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alene A.","family":"Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"O\u2019Keeffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5556-4618","authenticated-orcid":false,"given":"Jeffrey A.","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"3","key":"1175_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/BOR.0000000000000787","volume":"33","author":"GC McDermott","year":"2021","unstructured":"McDermott GC, Doyle TJ, Sparks JA. Interstitial lung disease throughout the rheumatoid arthritis disease course. Curr Opin Rheumatol. 2021;33(3):284\u201391.","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"1175_CR2","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1093\/rheumatology\/keaa836","volume":"60","author":"JA Sparks","year":"2021","unstructured":"Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford). 2021;60(8):3689\u201398.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1175_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40674-020-00160-z","volume":"6","author":"S Huang","year":"2020","unstructured":"Huang S, Kronzer VL, Dellaripa PF, Deane KD, Bolster MB, Nagaraja V, et al. Rheumatoid arthritis-associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment. Curr Treatm Opt Rheumatol. 2020;6(4):337\u201353.","journal-title":"Curr Treatm Opt Rheumatol."},{"issue":"5","key":"1175_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3899\/jrheum.200863","volume":"48","author":"VL Kronzer","year":"2021","unstructured":"Kronzer VL, Huang W, Dellaripa PF, Huang S, Feathers V, Lu B, et al. Lifestyle and clinical risk factors for incident rheumatoid arthritis-associated interstitial lung disease. J Rheumatol. 2021;48(5):656\u201363.","journal-title":"J Rheumatol"},{"issue":"11","key":"1175_CR5","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.42162","volume":"74","author":"PA Juge","year":"2022","unstructured":"Juge PA, Granger B, Debray MP, Ebstein E, Louis-Sidney F, Kedra J, et al. A risk score to detect subclinical rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2022;74(11):1755\u201365.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1175_CR6","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.40904","volume":"71","author":"JA Sparks","year":"2019","unstructured":"Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, et al. Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study. Arthritis Rheumatol. 2019;71(9):1472\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1175_CR7","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/rheumatology\/keab891","volume":"61","author":"AJ Esposito","year":"2022","unstructured":"Esposito AJ, Sparks JA, Gill RR, Hatabu H, Schmidlin EJ, Hota PV, et al. Screening for preclinical parenchymal lung disease in rheumatoid arthritis. Rheumatology (Oxford). 2022;61(8):3234\u201345.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1175_CR8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1002\/art.27405","volume":"62","author":"T Bongartz","year":"2010","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62(6):1583\u201391.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1175_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1378\/chest.13-1394","volume":"146","author":"TJ Doyle","year":"2014","unstructured":"Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014;146(1):41\u201350.","journal-title":"Chest"},{"issue":"4","key":"1175_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3899\/jrheum.171315","volume":"46","author":"K Raimundo","year":"2019","unstructured":"Raimundo K, Solomon JJ, Olson AL, Kong AM, Cole AL, Fischer A, et al. Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality. J Rheumatol. 2019;46(4):360\u20139.","journal-title":"J Rheumatol"},{"key":"1175_CR11","doi-asserted-by":"crossref","unstructured":"McDermott GC, Hayashi K, Juge PA, Gill R, Byrne S, Gagne S, et al. Impact of sex, serostatus, and smoking on risk for rheumatoid arthritis-associated interstitial lung disease subtypes. Arthritis Care Res (Hoboken). 2024.","DOI":"10.1002\/acr.25432"},{"issue":"8","key":"1175_CR12","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1007\/s10067-024-07028-w","volume":"43","author":"RK Venkat","year":"2024","unstructured":"Venkat RK, Hayashi K, Juge PA, McDermott G, Paudel M, Wang X, et al. Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2024;43(8):2453\u201366.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"1175_CR13","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/annrheumdis-2021-220698","volume":"80","author":"A Palomaki","year":"2021","unstructured":"Palomaki A, Palotie A, Koskela J, Eklund KK, Pirinen M, FinnGen Rheumatology Clinical Expert G, et al. Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers. Ann Rheum Dis. 2021;80(12):1530\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1175_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/thorax-2023-220022","volume":"79","author":"TJ Doyle","year":"2024","unstructured":"Doyle TJ, Juge PA, Peljto AL, Lee S, Walts AD, Esposito AJ, et al. Short peripheral blood leukocyte telomere length in rheumatoid arthritis-interstitial lung disease. Thorax. 2024;79(2):182\u20135.","journal-title":"Thorax"},{"issue":"12","key":"1175_CR15","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1093\/rheumatology\/keac152","volume":"61","author":"G McDermott","year":"2022","unstructured":"McDermott G, Gill R, Gagne S, Byrne S, Huang W, Cui J, et al. Associations of the MUC5B promoter variant with timing of interstitial lung disease and rheumatoid arthritis onset. Rheumatology (Oxford). 2022;61(12):4915\u201323.","journal-title":"Rheumatology (Oxford)"},{"issue":"23","key":"1175_CR16","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"PA Juge","year":"2018","unstructured":"Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B Promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med. 2018;379(23):2209\u201319.","journal-title":"N Engl J Med"},{"issue":"8","key":"1175_CR17","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/art.42860","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1201\u201313.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1175_CR18","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/acr.25347","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res (Hoboken). 2024;76(8):1070\u201382.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"8","key":"1175_CR19","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1182\u2013200.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1175_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/acr.25348","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Care Res (Hoboken). 2024;76(8):1051\u201369.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1175_CR21","doi-asserted-by":"crossref","unstructured":"Saavedra AA MK, Kowalski EN, Qian G, Bade KJ, Vanni KMM, McDermott GC, Sparks JA. Treatment of rheumatoid arthritis-associated interstitial lung disease: an appraisal of the 2023 ACR\/CHEST guideline. Curr Treatm Opt Rheumatol. 2024.","DOI":"10.1007\/s40674-024-00217-3"},{"issue":"Suppl 1","key":"1175_CR22","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1177\/096120330501400102","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005;14(Suppl 1):s2-8.","journal-title":"Lupus"},{"issue":"21","key":"1175_CR23","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research N, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968\u201377.","journal-title":"N Engl J Med"},{"key":"1175_CR24","doi-asserted-by":"crossref","unstructured":"Yuan H, Cui S, Yang L, Cui J, Wang X, Ding M, et al. Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. RMD Open. 2023;9(4).","DOI":"10.1136\/rmdopen-2023-003487"},{"issue":"6","key":"1175_CR25","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.42075","volume":"74","author":"EL Matteson","year":"2022","unstructured":"Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, et al. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD Trial. Arthritis Rheumatol. 2022;74(6):1039\u201347.","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"1175_CR26","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"11","key":"1175_CR27","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1007\/s12325-019-01086-2","volume":"36","author":"JJ Solomon","year":"2019","unstructured":"Solomon JJ, Danoff SK, Goldberg HJ, Woodhead F, Kolb M, Chambers DC, et al. The design and rationale of the Trail1 Trial: a randomized double-blind phase 2 clinical trial of pirfenidone in rheumatoid arthritis-associated interstitial lung disease. Adv Ther. 2019;36(11):3279\u201387.","journal-title":"Adv Ther"},{"issue":"1","key":"1175_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","volume":"11","author":"JJ Solomon","year":"2023","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023;11(1):87\u201396.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"1175_CR29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1175_CR30","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1007\/s10238-023-01163-5","volume":"23","author":"M Shirata","year":"2023","unstructured":"Shirata M, Ito I, Tanaka M, Murata K, Murakami K, Ikeda H, et al. Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Clin Exp Med. 2023;23(8):4707\u201320.","journal-title":"Clin Exp Med"},{"key":"1175_CR31","doi-asserted-by":"crossref","unstructured":"Andreica I, Blazquez-Navarro A, Sokolar J, Anft M, Kiltz U, Pfaender S, et al. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination. RMD Open. 2022;8(2).","DOI":"10.1136\/rmdopen-2022-002293"},{"issue":"1","key":"1175_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/13.1.160","volume":"13","author":"KG Smith","year":"1998","unstructured":"Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant. 1998;13(1):160\u20134.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1175_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","volume":"149","author":"N Cooper","year":"2010","unstructured":"Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149(1):3\u201313.","journal-title":"Br J Haematol"},{"issue":"12","key":"1175_CR34","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1093\/ndt\/gfn387","volume":"23","author":"R Hanvesakul","year":"2008","unstructured":"Hanvesakul R, Kubal C, Jham S, Sarkar E, Eardley K, Adu D, et al. Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients. Nephrol Dial Transplant. 2008;23(12):4049\u201353.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"1175_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-0044-1782218","volume":"45","author":"JV Pugashetti","year":"2024","unstructured":"Pugashetti JV, Lee JS. Overview of rheumatoid arthritis-associated interstitial lung disease and its treatment. Semin Respir Crit Care Med. 2024;45(3):329\u201341.","journal-title":"Semin Respir Crit Care Med."},{"issue":"9","key":"1175_CR36","first-page":"870","volume":"367","author":"S Izumi","year":"2012","unstructured":"Izumi S, Iikura M, Hirano S. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;367(9):870 (author reply -1).","journal-title":"N Engl J Med"},{"key":"1175_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.671503","volume":"12","author":"J Tieu","year":"2021","unstructured":"Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, et al. Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol. 2021;12: 671503.","journal-title":"Front Immunol"},{"key":"1175_CR38","doi-asserted-by":"publisher","first-page":"1024068","DOI":"10.3389\/fimmu.2022.1024068","volume":"13","author":"JM Hartinger","year":"2022","unstructured":"Hartinger JM, Kratky V, Hruskova Z, Slanar O, Tesar V. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives. Front Immunol. 2022;13:1024068.","journal-title":"Front Immunol"},{"issue":"1","key":"1175_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14999","volume":"27","author":"K Hata","year":"2024","unstructured":"Hata K, Kotani T, Matsuda S, Fujiki Y, Suzuka T, Kiboshi T, et al. Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease. Int J Rheum Dis. 2024;27(1): e14999.","journal-title":"Int J Rheum Dis"},{"issue":"17","key":"1175_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010228","volume":"97","author":"J Wang","year":"2018","unstructured":"Wang J, Zhao J, Fei X, Yin Y, Cheng H, Zhang W, et al. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia. Medicine (Baltimore). 2018;97(17): e0228.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"1175_CR41","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"1175_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrrheum.2013.197","volume":"10","author":"M Jani","year":"2014","unstructured":"Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol. 2014;10(5):284\u201394.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1175_CR43","doi-asserted-by":"publisher","first-page":"rkad065","DOI":"10.1093\/rap\/rkad065","volume":"7","author":"A Schafer","year":"2023","unstructured":"Schafer A, Kovacs MS, Eder A, Nigg A, Feuchtenberger M. TNF inhibitors significantly attenuate the humoral immune response to COVID-19 vaccination in patients with rheumatoid arthritis. Rheumatol Adv Pract. 2023;7(2):rkad065.","journal-title":"Rheumatol Adv Pract."},{"issue":"2","key":"1175_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","volume":"63","author":"CC Mok","year":"2024","unstructured":"Mok CC, So H, Yim CW, To CH, Lao WN, Wong SPY, et al. Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry. Rheumatology (Oxford). 2024;63(2):358\u201365.","journal-title":"Rheumatology (Oxford)"},{"key":"1175_CR45","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y, et al. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. 2022;8(1).","DOI":"10.1136\/rmdopen-2021-002012"},{"issue":"3","key":"1175_CR46","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","volume":"24","author":"JR Berger","year":"2018","unstructured":"Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol. 2018;24(3):323\u201331.","journal-title":"J Neurovirol"},{"issue":"1","key":"1175_CR47","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","volume":"10","author":"MH Kuo","year":"2020","unstructured":"Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate risk of hepatitis B virus reactivation in HBsAg(\u2212)\/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis. Sci Rep. 2020;10(1):2456.","journal-title":"Sci Rep"},{"key":"1175_CR48","doi-asserted-by":"crossref","unstructured":"Leacy EJ, Teh JW, O'Rourke AM, Brady G, Gargan S, Conlon N, et al. Effect of immunosuppression on the immune response to SARS-CoV-2 infection and vaccination. Int J Mol Sci. 2024;25(10).","DOI":"10.3390\/ijms25105239"},{"issue":"1","key":"1175_CR49","doi-asserted-by":"publisher","first-page":"2390227","DOI":"10.1080\/21645515.2024.2390227","volume":"20","author":"A Addario","year":"2024","unstructured":"Addario A, Pardo M, Gavazzi G, Bongue B, Celarier T, Dorier S, et al. The desire of autonomy: a lever for vaccination of the elderly? Results of a qualitative study. Hum Vaccin Immunother. 2024;20(1):2390227.","journal-title":"Hum Vaccin Immunother"},{"key":"1175_CR50","doi-asserted-by":"crossref","unstructured":"Xia T, Zhou Y, An J, Cui Z, Zhong X, Cui T, et al. Benefit delayed immunosenescence by regulating CD4(+)T cells: a promising therapeutic target for aging-related diseases. Aging Cell. 2024:e14317.","DOI":"10.1111\/acel.14317"},{"key":"1175_CR51","doi-asserted-by":"crossref","unstructured":"Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6(1).","DOI":"10.1136\/rmdopen-2017-000536"},{"issue":"1","key":"1175_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","volume":"42","author":"J Youssef","year":"2016","unstructured":"Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 2016;42(1):157\u201376 (ix\u2013x).","journal-title":"Rheum Dis Clin North Am"},{"key":"1175_CR53","doi-asserted-by":"crossref","unstructured":"Mena-Vazquez N, Garcia-Studer A, Rojas-Gimenez M, Romero-Barco CM, Manrique-Arija S, Mucientes A, et al. Importance of vaccination against SARS-CoV-2 in patients with interstitial lung disease associated with systemic autoimmune disease. J Clin Med. 2022;11(9).","DOI":"10.3390\/jcm11092437"},{"issue":"1","key":"1175_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"29","key":"1175_CR55","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","volume":"72","author":"M Melgar","year":"2023","unstructured":"Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices\u2014United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793\u2013801.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"1175_CR56","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s12026-023-09367-3","volume":"71","author":"AE In \u2018t Veld","year":"2023","unstructured":"In \u2018t Veld AE, Grievink HW, van der Plas JL, Eveleens Maarse BC, van Kraaij SJW, Woutman TD, et al. Immunosuppression by hydroxychloroquine: mechanistic proof in in vitro experiments but limited systemic activity in a randomized placebo-controlled clinical pharmacology study. Immunol Res. 2023;71(4):617\u201327.","journal-title":"Immunol Res"},{"issue":"3","key":"1175_CR57","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1175_CR58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/acr.23826","volume":"72","author":"C Rempenault","year":"2020","unstructured":"Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, et al. Clinical and structural efficacy of hydroxychloroquine in rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken). 2020;72(1):36\u201340.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1175_CR59","doi-asserted-by":"crossref","unstructured":"Yeh JJ, Syue SH, Sun YF, Yeh YT, Zheng YC, Lin CL, et al. Hydroxychloroquine on the pulmonary vascular diseases in interstitial lung disease: immunologic effects, and virus interplay. Biomedicines. 2022;10(6).","DOI":"10.3390\/biomedicines10061290"},{"issue":"5","key":"1175_CR60","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/acr.23346","volume":"70","author":"TC Lin","year":"2018","unstructured":"Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of hepatitis B virus reactivation in patients with inflammatory arthritis receiving disease-modifying antirheumatic drugs: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2018;70(5):724\u201331.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"6","key":"1175_CR61","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717\u201322.","journal-title":"Clin Infect Dis"},{"key":"1175_CR62","doi-asserted-by":"crossref","unstructured":"Furer V, Elkayam O. Dual biologic therapy in patients with rheumatoid arthritis and psoriatic arthritis. Rambam Maimonides Med J. 2023;14(2).","DOI":"10.5041\/RMMJ.10494"},{"issue":"5","key":"1175_CR63","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/1759720X16665330","volume":"8","author":"K Inui","year":"2016","unstructured":"Inui K, Koike T. Combination therapy with biologic agents in rheumatic diseases: current and future prospects. Ther Adv Musculoskelet Dis. 2016;8(5):192\u2013202.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"3","key":"1175_CR64","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","volume":"50","author":"L Campbell","year":"2011","unstructured":"Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50(3):552\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1175_CR65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semarthrit.2018.12.003","volume":"49","author":"G Boleto","year":"2019","unstructured":"Boleto G, Kanagaratnam L, Drame M, Salmon JH. Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2019;49(1):35\u201342.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1175_CR66","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00408-019-00260-1","volume":"197","author":"VLJ Proesmans","year":"2019","unstructured":"Proesmans VLJ, Drent M, Elfferich MDP, Wijnen P, Jessurun NT, Bast A. Self-reported gastrointestinal side effects of antifibrotic drugs in Dutch idiopathic pulmonary fibrosis patients. Lung. 2019;197(5):551\u20138.","journal-title":"Lung"},{"issue":"4","key":"1175_CR67","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","volume":"210","author":"L Lancaster","year":"2024","unstructured":"Lancaster L, Cottin V, Ramaswamy M, Wuyts WA, Jenkins RG, Scholand MB, et al. Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial. Am J Respir Crit Care Med. 2024;210(4):424\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"1175_CR68","volume":"13","author":"BA Bani Fawwaz","year":"2021","unstructured":"Bani Fawwaz BA, Aldwairy A, Farooq A. Mycophenolate-induced colitis: a rare side effect. Cureus. 2021;13(9): e18250.","journal-title":"Cureus."},{"issue":"9","key":"1175_CR69","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1097\/PAS.0b013e31816bf3fe","volume":"32","author":"JR Parfitt","year":"2008","unstructured":"Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastrointestinal mucosal injury: variable injury patterns, including graft-versus-host disease-like changes. Am J Surg Pathol. 2008;32(9):1367\u201372.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1175_CR70","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10245330701283959","volume":"12","author":"VS Richard","year":"2007","unstructured":"Richard VS, Al-Ismail D, Salamat A. Should we test TPMT enzyme levels before starting azathioprine? Hematology. 2007;12(4):359\u201360.","journal-title":"Hematology"},{"issue":"5","key":"1175_CR71","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390\u2013400.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1175_CR72","first-page":"1487","volume":"66","author":"JH Fetting","year":"1982","unstructured":"Fetting JH, Grochow LB, Folstein MF, Ettinger DS, Colvin M. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep. 1982;66(7):1487\u201393.","journal-title":"Cancer Treat Rep"},{"issue":"39","key":"1175_CR73","doi-asserted-by":"publisher","first-page":"8844","DOI":"10.3748\/wjg.v22.i39.8844","volume":"22","author":"LS Yang","year":"2016","unstructured":"Yang LS, Cameron K, Papaluca T, Basnayake C, Jackett L, McKelvie P, et al. Cyclophosphamide-associated enteritis: a rare association with severe enteritis. World J Gastroenterol. 2016;22(39):8844\u20138.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1175_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000496331","volume":"12","author":"T Tanaka","year":"2019","unstructured":"Tanaka T, Nakashima Y, Sasaki H, Masaki M, Mogi A, Tamura K, et al. Severe hemorrhagic cystitis caused by cyclophosphamide and capecitabine therapy in breast cancer patients: two case reports and literature review. Case Rep Oncol. 2019;12(1):69\u201375.","journal-title":"Case Rep Oncol"},{"issue":"2","key":"1175_CR75","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/0003-4819-91-2-221","volume":"91","author":"PH Plotz","year":"1979","unstructured":"Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, et al. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med. 1979;91(2):221\u20133.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1175_CR76","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17512433.2024.2396121","volume":"17","author":"K Aribindi","year":"2024","unstructured":"Aribindi K, Liu GY, Albertson TE. Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF). Expert Rev Clin Pharmacol. 2024;17(9):817\u201335.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1175_CR77","unstructured":"David M, Dieude P, Debray MP, Le Guen P, Crestani B, Borie R. Low-dose methotrexate: indications and side effects, particularly in cases of diffuse interstitial pneumonia. Rev Mal Respir. 2024."},{"issue":"5","key":"1175_CR78","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/ard.62.5.423","volume":"62","author":"M Hoekstra","year":"2003","unstructured":"Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):423\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1175_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15029","volume":"27","author":"M Kanda","year":"2024","unstructured":"Kanda M, Sato M, Nagahata K, Naishiro Y, Murakami R, Honda S, et al. Assessment of oral methotrexate intolerance in Japanese adult patients with rheumatoid arthritis. Int J Rheum Dis. 2024;27(1): e15029.","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"1175_CR80","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/keab438","volume":"61","author":"C Rempenault","year":"2022","unstructured":"Rempenault C, Lukas C, Combe B, Herrero A, Pane I, Schaeverbeke T, et al. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (Oxford). 2022;61(3):953\u201362.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1175_CR81","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1055\/s-0037-1607464","volume":"31","author":"ST Munie","year":"2018","unstructured":"Munie ST, Nalamati SPM. Epidemiology and pathophysiology of diverticular disease. Clin Colon Rectal Surg. 2018;31(4):209\u201313.","journal-title":"Clin Colon Rectal Surg"},{"issue":"6","key":"1175_CR82","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172(6):369\u201380.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1175_CR83","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137\u201346.","journal-title":"J Clin Invest"},{"issue":"4","key":"1175_CR84","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.18632\/oncotarget.12739","volume":"8","author":"D Ribatti","year":"2017","unstructured":"Ribatti D. The concept of immune surveillance against tumors. The first theories. Oncotarget. 2017;8(4):7175\u201380.","journal-title":"Oncotarget"},{"issue":"10","key":"1175_CR85","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715\u201327.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1175_CR86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12885-022-10497-4","volume":"23","author":"S Ilham","year":"2023","unstructured":"Ilham S, Willis C, Kim K, Chung KC, Wood BM, Tan MS, et al. Cancer incidence in immunocompromised patients: a single-center cohort study. BMC Cancer. 2023;23(1):33.","journal-title":"BMC Cancer"},{"issue":"3","key":"1175_CR87","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nri1310","volume":"4","author":"TS Kupper","year":"2004","unstructured":"Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol. 2004;4(3):211\u201322.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1175_CR88","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","volume":"185","author":"T Vial","year":"2003","unstructured":"Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology. 2003;185(3):229\u201340.","journal-title":"Toxicology"},{"issue":"4","key":"1175_CR89","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4078\/jrd.22.0034","volume":"29","author":"CH Jeon","year":"2022","unstructured":"Jeon CH. Rheumatoid arthritis and malignancy: what should we do with DMARDs? J Rheum Dis. 2022;29(4):191\u20132.","journal-title":"J Rheum Dis"},{"issue":"3","key":"1175_CR90","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/acr.23865","volume":"72","author":"MA Lopez-Olivo","year":"2020","unstructured":"Lopez-Olivo MA, Colmegna I, Karpes Matusevich AR, Qi SR, Zamora NV, Sharma R, et al. Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res (Hoboken). 2020;72(3):309\u201318.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"3","key":"1175_CR91","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4078\/jrd.2022.29.3.162","volume":"29","author":"YB Joo","year":"2022","unstructured":"Joo YB, Jeong SM, Park YJ, Kim KJ, Park KS. Use of disease-modifying antirheumatic drugs after cancer diagnosis in rheumatoid arthritis patients. J Rheum Dis. 2022;29(3):162\u201370.","journal-title":"J Rheum Dis"},{"issue":"1","key":"1175_CR92","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","volume":"7","author":"P Emery","year":"2020","unstructured":"Emery P, Furst DE, Kirchner P, Melega S, Lacey S, Lehane PB. Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data. Rheumatol Ther. 2020;7(1):121\u201331.","journal-title":"Rheumatol Ther."},{"issue":"9","key":"1175_CR93","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1175_CR94","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1742-7843.2009.00375.x","volume":"104","author":"R Korhonen","year":"2009","unstructured":"Korhonen R, Moilanen E. Abatacept, a novel CD80\/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2009;104(4):276\u201384.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"1175_CR95","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","volume":"77","author":"HA Blair","year":"2017","unstructured":"Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs. 2017;77(11):1221\u201333.","journal-title":"Drugs"},{"issue":"12","key":"1175_CR96","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nri3108","volume":"11","author":"LS Walker","year":"2011","unstructured":"Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852\u201363.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1175_CR97","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","volume":"37","author":"A Hoos","year":"2010","unstructured":"Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37(5):533\u201346.","journal-title":"Semin Oncol"},{"issue":"22","key":"1175_CR98","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","volume":"17","author":"EJ Lipson","year":"2011","unstructured":"Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958\u201362.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1175_CR99","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40265-013-0080-9","volume":"73","author":"GM Keating","year":"2013","unstructured":"Keating GM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(10):1095\u2013119.","journal-title":"Drugs"},{"issue":"4","key":"1175_CR100","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/rheumatology\/key352","volume":"58","author":"F Montastruc","year":"2019","unstructured":"Montastruc F, Renoux C, Dell\u2019Aniello S, Simon TA, Azoulay L, Hudson M, et al. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology (Oxford). 2019;58(4):683\u201391.","journal-title":"Rheumatology (Oxford)"},{"key":"1175_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7:41.","journal-title":"J Inflamm (Lond)"},{"issue":"4","key":"1175_CR102","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326.","journal-title":"N Engl J Med"},{"issue":"3 Suppl 1","key":"1175_CR103","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Henley SJ. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-15.","journal-title":"Am J Prev Med"},{"key":"1175_CR104","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.","DOI":"10.1161\/circ.106.25.3143"},{"issue":"4","key":"1175_CR105","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/ard.2008.101964","volume":"68","author":"E Choy","year":"2009","unstructured":"Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1175_CR106","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.semarthrit.2008.01.015","volume":"38","author":"G Steiner","year":"2009","unstructured":"Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum. 2009;38(5):372\u201381.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1175_CR107","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1175_CR108","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70(3):482\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1175_CR109","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/art.41095","volume":"72","author":"JT Giles","year":"2020","unstructured":"Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31\u201340.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1175_CR110","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","volume":"46","author":"V Yang","year":"2023","unstructured":"Yang V, Kragstrup TW, McMaster C, Reid P, Singh N, Haysen SR, et al. Managing cardiovascular and cancer risk associated with JAK inhibitors. Drug Saf. 2023;46(11):1049\u201371.","journal-title":"Drug Saf"},{"issue":"9","key":"1175_CR111","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.32766","volume":"5","author":"CT Cigolle","year":"2022","unstructured":"Cigolle CT, Blaum CS, Lyu C, Ha J, Kabeto M, Zhong J. Associations of age at diagnosis and duration of diabetes with morbidity and mortality among older adults. JAMA Netw Open. 2022;5(9): e2232766.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1175_CR112","doi-asserted-by":"publisher","first-page":"2368798","DOI":"10.1080\/08037051.2024.2368798","volume":"33","author":"A Laati","year":"2024","unstructured":"Laati A, Teppo K, Vire J, Viitanen M, Langen V. The natural history of hypertension in older adults: a study of two Finnish generational cohorts born 20 years apart. Blood Press. 2024;33(1):2368798.","journal-title":"Blood Press"},{"issue":"9","key":"1175_CR113","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41581-024-00863-9","volume":"20","author":"NC Chesnaye","year":"2024","unstructured":"Chesnaye NC, Ortiz A, Zoccali C, Stel VS, Jager KJ. The impact of population ageing on the burden of chronic kidney disease. Nat Rev Nephrol. 2024;20(9):569\u201385.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"1175_CR114","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/dmrr.2486","volume":"30","author":"JL Hwang","year":"2014","unstructured":"Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96\u2013102.","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"1175_CR115","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.4239\/wjd.v6.i8.1073","volume":"6","author":"HE Tamez-Perez","year":"2015","unstructured":"Tamez-Perez HE, Quintanilla-Flores DL, Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Tamez-Pena AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073\u201381.","journal-title":"World J Diabetes"},{"issue":"9","key":"1175_CR116","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s13300-024-01628-0","volume":"15","author":"AB Jain","year":"2024","unstructured":"Jain AB, Lai V. Medication-induced hyperglycemia and diabetes mellitus: a review of current literature and practical management strategies. Diabetes Ther. 2024;15(9):2001\u201325.","journal-title":"Diabetes Ther."},{"issue":"5","key":"1175_CR117","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"JR Petrie","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575\u201384.","journal-title":"Can J Cardiol"},{"issue":"1","key":"1175_CR118","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)."},{"issue":"23","key":"1175_CR119","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033984","volume":"102","author":"C Elendu","year":"2023","unstructured":"Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, et al. Comprehensive review of current management guidelines of chronic kidney disease. Medicine (Baltimore). 2023;102(23): e33984.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"1175_CR120","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jaip.2018.02.007","volume":"6","author":"AP Baptist","year":"2018","unstructured":"Baptist AP, Busse PJ. Asthma over the age of 65: all\u2019s well that ends well. J Allergy Clin Immunol Pract. 2018;6(3):764\u201373.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"1175_CR121","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.cger.2017.06.006","volume":"33","author":"F Cortopassi","year":"2017","unstructured":"Cortopassi F, Gurung P, Pinto-Plata V. Chronic obstructive pulmonary disease in elderly patients. Clin Geriatr Med. 2017;33(4):539\u201352.","journal-title":"Clin Geriatr Med"},{"key":"1175_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2024.117204","volume":"187","author":"M Zoulakis","year":"2024","unstructured":"Zoulakis M, Axelsson KF, Litsne H, Johansson L, Lorentzon M. Real-world effectiveness of osteoporosis screening in older Swedish women (SUPERB). Bone. 2024;187: 117204.","journal-title":"Bone"},{"issue":"1","key":"1175_CR123","doi-asserted-by":"publisher","first-page":"2356510","DOI":"10.1080\/15412555.2024.2356510","volume":"21","author":"A Penedones","year":"2024","unstructured":"Penedones A, Mendes D, Alves C, Filipe A, Oliveira T, Batel-Marques F. Relationship between chronic obstructive pulmonary disease and osteoporosis: a scoping review. COPD. 2024;21(1):2356510.","journal-title":"COPD"},{"issue":"12","key":"1175_CR124","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1359\/jbmr.1998.13.12.1915","volume":"13","author":"LJ Melton 3rd","year":"1998","unstructured":"Melton LJ 3rd, Atkinson EJ, O\u2019Connor MK, O\u2019Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998;13(12):1915\u201323.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"1175_CR125","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/s41433-020-0806-3","volume":"34","author":"H Hashemi","year":"2020","unstructured":"Hashemi H, Pakzad R, Yekta A, Aghamirsalim M, Pakbin M, Ramin S, et al. Global and regional prevalence of age-related cataract: a comprehensive systematic review and meta-analysis. Eye (Lond). 2020;34(8):1357\u201370.","journal-title":"Eye (Lond)"},{"key":"1175_CR126","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ajo.2024.08.017","volume":"269","author":"SH Lee","year":"2024","unstructured":"Lee SH, Tseng BY, Wu MC, Wang JH, Chiu CJ. Incidence and progression of diabetic retinopathy after cataract surgery: a systematic review and meta-analysis. Am J Ophthalmol. 2024;269:105\u201315.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1175_CR127","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40801-016-0093-2","volume":"3","author":"T Gu","year":"2016","unstructured":"Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF. Comparing biologic cost per treated patient across indications among adult us managed care patients: a retrospective cohort study. Drugs Real World Outcomes. 2016;3(4):369\u201381.","journal-title":"Drugs Real World Outcomes."},{"issue":"3","key":"1175_CR128","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.5429","volume":"5","author":"K Feng","year":"2024","unstructured":"Feng K, Russo M, Maini L, Kesselheim AS, Rome BN. Patient out-of-pocket costs for biologic drugs after biosimilar competition. JAMA Health Forum. 2024;5(3): e235429.","journal-title":"JAMA Health Forum."},{"issue":"8","key":"1175_CR129","doi-asserted-by":"publisher","first-page":"E668","DOI":"10.1001\/amajethics.2019.668","volume":"21","author":"MZ Zhai","year":"2019","unstructured":"Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668\u201378.","journal-title":"AMA J Ethics"},{"issue":"1","key":"1175_CR130","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12890-022-01922-2","volume":"22","author":"AW Wong","year":"2022","unstructured":"Wong AW, Koo J, Ryerson CJ, Sadatsafavi M, Chen W. A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies. BMC Pulm Med. 2022;22(1):148.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"1175_CR131","first-page":"32","volume":"100","author":"AD Halli-Tierney","year":"2019","unstructured":"Halli-Tierney AD, Scarbrough C, Carroll D. Polypharmacy: evaluating risks and deprescribing. Am Fam Physician. 2019;100(1):32\u20138.","journal-title":"Am Fam Physician"},{"issue":"4","key":"1175_CR132","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.4103\/jfmpc.jfmpc_1302_20","volume":"10","author":"S Punnapurath","year":"2021","unstructured":"Punnapurath S, Vijayakumar P, Platty PL, Krishna S, Thomas T. A study of medication compliance in geriatric patients with chronic illness. J Fam Med Prim Care. 2021;10(4):1644\u20138.","journal-title":"J Fam Med Prim Care."},{"issue":"9","key":"1175_CR133","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1007\/s12325-019-01037-x","volume":"36","author":"K Moran","year":"2019","unstructured":"Moran K, Null K, Huang Z, Lissoos T, Kane S. Retrospective claims analysis indirectly comparing medication adherence and persistence between intravenous biologics and oral small-molecule therapies in inflammatory bowel diseases. Adv Ther. 2019;36(9):2260\u201372.","journal-title":"Adv Ther"},{"issue":"3","key":"1175_CR134","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1001\/jamainternmed.2023.7628","volume":"184","author":"LM Kern","year":"2024","unstructured":"Kern LM, Bynum JPW, Pincus HA. Care fragmentation, care continuity, and care coordination-how they differ and why it matters. JAMA Intern Med. 2024;184(3):236\u20137.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"1175_CR135","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/j.pec.2022.03.015","volume":"105","author":"MR Eastman","year":"2022","unstructured":"Eastman MR, Kalesnikava VA, Mezuk B. Experiences of care coordination among older adults in the United States: evidence from the Health and retirement study. Patient Educ Couns. 2022;105(7):2429\u201335.","journal-title":"Patient Educ Couns"},{"issue":"10","key":"1175_CR136","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565\u201381.","journal-title":"Nat Rev Neurol"},{"key":"1175_CR137","doi-asserted-by":"crossref","unstructured":"Erkkinen MG, Kim MO, Geschwind MD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10(4).","DOI":"10.1101\/cshperspect.a033118"},{"issue":"6","key":"1175_CR138","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1056\/NEJMra2301292","volume":"391","author":"DH Kim","year":"2024","unstructured":"Kim DH, Rockwood K. Frailty in older adults. N Engl J Med. 2024;391(6):538\u201348.","journal-title":"N Engl J Med"},{"issue":"6","key":"1175_CR139","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/modpathol.2009.44","volume":"22","author":"MK Selbst","year":"2009","unstructured":"Selbst MK, Ahrens WA, Robert ME, Friedman A, Proctor DD, Jain D. Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil. Mod Pathol. 2009;22(6):737\u201343.","journal-title":"Mod Pathol"},{"issue":"8","key":"1175_CR140","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/00007890-199810270-00027","volume":"66","author":"D Ducloux","year":"1998","unstructured":"Ducloux D, Ottignon Y, Semhoun-Ducloux S, Labbe S, Saint-Hillier Y, Miguet JP, et al. Mycophenolate mofetil-induced villous atrophy. Transplantation. 1998;66(8):1115\u20136.","journal-title":"Transplantation"},{"key":"1175_CR141","doi-asserted-by":"crossref","unstructured":"Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context. 2021;10.","DOI":"10.7573\/dic.2020-8-8"},{"issue":"4","key":"1175_CR142","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/2040622313485275","volume":"4","author":"K Orlicka","year":"2013","unstructured":"Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4(4):167\u201385.","journal-title":"Ther Adv Chronic Dis."},{"issue":"4","key":"1175_CR143","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","volume":"168","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med. 2008;168(4):378\u201381.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1175_CR144","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1093\/rheumatology\/keu372","volume":"54","author":"M Faurschou","year":"2015","unstructured":"Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(8):1345\u201350.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1175_CR145","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.urolonc.2021.05.017","volume":"39","author":"WH Chou","year":"2021","unstructured":"Chou WH, McGregor B, Schmidt A, Carvalho FLF, Hirsch MS, Chang SL, et al. Cyclophosphamide-associated bladder cancers and considerations for survivorship care: a systematic review. Urol Oncol. 2021;39(10):678\u201385.","journal-title":"Urol Oncol"},{"issue":"5","key":"1175_CR146","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2165\/00003495-199142050-00005","volume":"42","author":"LH Fraiser","year":"1991","unstructured":"Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs. 1991;42(5):781\u201395.","journal-title":"Drugs"},{"issue":"11","key":"1175_CR147","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/aje\/153.11.1089","volume":"153","author":"S Hernandez-Diaz","year":"2001","unstructured":"Hernandez-Diaz S, Rodriguez LA. Steroids and risk of upper gastrointestinal complications. Am J Epidemiol. 2001;153(11):1089\u201393.","journal-title":"Am J Epidemiol"},{"issue":"11","key":"1175_CR148","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard-2023-224185","volume":"82","author":"H So","year":"2023","unstructured":"So H, Lam TO, Meng H, Lam SHM, Tam LS. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study. Ann Rheum Dis. 2023;82(11):1387\u201393.","journal-title":"Ann Rheum Dis"},{"key":"1175_CR149","doi-asserted-by":"crossref","unstructured":"Coburn BW, Baker JF, Hsu JY, Wu Q, Xie F, Curtis JR, et al. Association of cardiovascular outcomes with low-dose glucocorticoid prescription in patients with rheumatoid arthritis. Arthritis Rheumatol. 2024.","DOI":"10.1002\/art.42928"},{"key":"1175_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2020.101380","volume":"55","author":"B Szmyd","year":"2021","unstructured":"Szmyd B, Rogut M, Bialasiewicz P, Gabryelska A. The impact of glucocorticoids and statins on sleep quality. Sleep Med Rev. 2021;55: 101380.","journal-title":"Sleep Med Rev"},{"key":"1175_CR151","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1749-6632.2009.04981.x","volume":"1179","author":"ES Brown","year":"2009","unstructured":"Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann NY Acad Sci. 2009;1179:41\u201355.","journal-title":"Ann NY Acad Sci"},{"issue":"12","key":"1175_CR152","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/acr2.11187","volume":"2","author":"KMM Vanni","year":"2020","unstructured":"Vanni KMM, Berliner N, Paynter NP, Glynn RJ, MacFadyen J, Colls J, et al. Adverse effects of low-dose methotrexate in a randomized double-blind placebo-controlled trial: adjudicated hematologic and skin cancer outcomes in the Cardiovascular Inflammation Reduction Trial. ACR Open Rheumatol. 2020;2(12):697\u2013704.","journal-title":"ACR Open Rheumatol."},{"issue":"3","key":"1175_CR153","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5414\/CP203604","volume":"58","author":"R Inose","year":"2020","unstructured":"Inose R, Hashimoto N, Hosomi K, Yokoyama S, Takada M. Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2020;58(3):131\u20138.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"1175_CR154","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752\u201362.","journal-title":"N Engl J Med"},{"issue":"2","key":"1175_CR155","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","volume":"59","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years\u2019 follow-up. Rheumatology (Oxford). 2020;59(2):292\u2013302.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1175_CR156","volume":"8","author":"J Adamski","year":"2021","unstructured":"Adamski J, Jaschke B, Nieminen T, Weigl W. Bowel perforation during haemophagocytic lymphohistiocytosis treatment with corticosteroids and anakinra. Eur J Case Rep Intern Med. 2021;8(10): 002759.","journal-title":"Eur J Case Rep Intern Med."},{"issue":"2","key":"1175_CR157","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","volume":"16","author":"YM Chiu","year":"2020","unstructured":"Chiu YM, Chen DY. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics. Expert Rev Clin Immunol. 2020;16(2):207\u201328.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01175-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01175-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T22:48:52Z","timestamp":1738795732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01175-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":157,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01175-0","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"15 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Sparks is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR080659, R01 AR077607, P30 AR070253, and P30 AR072577), National Heart, Lung, and Blood Institutes (grant number R01 HL155522), the R. Bruce and Joan M. Mickey Research Scholar Fund, and the Llura Gund Award funded by the Gordon and Llura Gund Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.A.S. has received research support from Boehringer Ingelheim, Bristol Myers Squibb, Janssen, and Sonoma Biotherapeutics unrelated to this work. He has performed consultancy for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Johnson & Johnson, Merck, MustangBio, Optum, Pfizer, ReCor, Sana, Sobi, and UCB unrelated to this work. The funders had no role in the decision to publish or preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health. All other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable; we did not prospectively enroll participants for this narrative review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable; no patient data were obtained for this narrative review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable; no statistical analyses were performed for this narrative review.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable; no data or material were collected for this narrative review.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability for data and material"}},{"value":"Not applicable; no ethics approval was required for this narrative review.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}